@article{745d1929b75e40a38a6b6a6466e71114,
title = "Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up",
author = "\{ESMO Guidelines Committee\} and M. Dreyling and E. Campo and O. Hermine and M. Jerkeman and \{Le Gouill\}, S. and S. Rule and O. Shpilberg and J. Walewski and M. Ladetto",
note = "Funding Information: MD has reported being a member of the advisory board of Bayer, Celgene, Gilead, Janssen, Mundipharma, Sandoz and Roche, received honoraria from Bayer, Celgene, Gilead, Janssen and Roche and research grants from Celgene, Janssen, Mundipharma, Pfizer and Roche; MJ received research support from Janssen, Celgene, Giliead and Abbvie; SLG has reported research grants 16. and honoraria from Roche Genentech and Jenssen-Cilag and honoraria from Celgene; OS has reported to be a member of the scientific advisory board for Roche, AbbVie, Gilead sciences and Takeda; JW has reported advisory board for Roche, Janssen-Cilag, Celgene, Amgen, Bristol-Myers Squibb and Incyte, received lecture honoraria from Roche, Takeda, Celgene, Servier, Gilead and Janssen-Cilag, research funding from Roche, Mundipharma, Celgene and GlaxoSmithKline/Novartis, and travel grants from Roche, Celgene, Sanofi and Servier; EC, OH, SR and ML have reported no conflict of interest.",
year = "2017",
doi = "10.1093/annonc/mdx223",
language = "אנגלית",
volume = "28",
pages = "iv62--iv71",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Elsevier Ltd.",
}